# Disc Medicine, Inc. (IRON)

> Source: Nexqual · https://nexqual.com/IRON · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Disc Medicine, Inc. (IRON), nexqual.com/IRON" · informational, not investment advice.

**Price:** USD 56.65 (+1.63% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 55.74 · day 55.95–58.09 · 52w 40–99.5 · market cap $2.17B · NGM

## Key facts
- Analysts: Buy (mean 1.92 on a 1–5 scale) (13 analysts), mean target USD 103.17 (range 83–128).
- Total return with dividends: 1Y -23.8% vs S&P 500 +18.1%; 5Y -49.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.71, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.92 on a 1–5 scale), 13 analysts; mean target USD 103.17 (low 83, high 128).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-16 | Wells Fargo | Target raised | Overweight | $79 → $86 |
| 2026-09-10 | Wedbush | Reiterated | Outperform | $100 |
| 2026-09-02 | Wedbush | Target raised | Outperform | $88 → $100 |
| 2026-08-06 | HC Wainwright & Co. | Target raised | Buy | $118 → $120 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -23.8% | -49.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -23.9% | -12.7% |
| Volatility (annualized) | 54.0% | 74.2% |
| Max drawdown | -40.8% (Nov 2025→Oct 2026) | -83.3% (Oct 2021→Jan 2023) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/IRON · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt